Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Payables (2016 - 2025)

Historic Payables for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to $40.4 million.

  • Northwest Biotherapeutics' Payables rose 5867.01% to $40.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.4 million, marking a year-over-year increase of 5867.01%. This contributed to the annual value of $31.2 million for FY2024, which is 11958.7% up from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Payables of $40.4 million as of Q3 2025, which was up 5867.01% from $40.0 million recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Payables registered a high of $40.4 million during Q3 2025, and its lowest value of $9.7 million during Q1 2021.
  • In the last 5 years, Northwest Biotherapeutics' Payables had a median value of $22.4 million in 2023 and averaged $24.0 million.
  • As far as peak fluctuations go, Northwest Biotherapeutics' Payables crashed by 4561.9% in 2023, and later soared by 11958.7% in 2024.
  • Over the past 5 years, Northwest Biotherapeutics' Payables (Quarter) stood at $14.1 million in 2021, then skyrocketed by 85.3% to $26.1 million in 2022, then plummeted by 45.62% to $14.2 million in 2023, then surged by 119.59% to $31.2 million in 2024, then grew by 29.82% to $40.4 million in 2025.
  • Its Payables stands at $40.4 million for Q3 2025, versus $40.0 million for Q2 2025 and $40.4 million for Q1 2025.